Drug intelligence / Profile preview

Argilive

Development stage: Unknown
Lead developer: Lifevision Healthcare
Administration: Oral

Overview

**Argilive** is an oral fixed-dose nutritional supplement marketed by Liveon Healthcare for pregnancy-related conditions including intrauterine growth restriction, pre-eclampsia, and oligohydramnios. Each tablet contains L-arginine 1000 mg and lycopene 2500 mcg. L-arginine is a substrate for endogenous nitric oxide production and is intended to support vasodilation and maternal-fetal nutrient perfusion, while lycopene provides antioxidant support intended to reduce oxidative stress. ([liveonhealthcare.com](https://liveonhealthcare.com/page/argilive))

Brand names: Argilive

Targets

NOS1 (nNOS)

Beyond the preview

Go deeper on Argilive.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Argilive.

Explore the full profile